Kings Global Biotech Limited’s Post

Thoughts on this? >> Arbutus reduces headcount after axing HBV combo trial that features Imfinzi >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #biotech #pharma #pharmaceutical

Thoughts on this? >> Arbutus reduces headcount after axing HBV combo trial that features Imfinzi >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #healthcare #biotech #pharma

MANKIND PHARMA LTD Pharma is set to acquire Bharat Serums and Vaccines Limited (BSV) from Advent International for approximately Rs 13,630 crore. Here’s what you need to know: 🎯 Strategic Acquisition: This move positions Mankind Pharma as a leader in the Indian women's health and fertility drug market. 💊 Portfolio Expansion: The acquisition includes high-entry barrier products in critical care, backed by advanced R&D technology platforms. 👨⚕️ Enhanced R&D Capabilities: BSV’s research teams will significantly bolster Mankind Pharma's existing R&D efforts. 💉 Biologics Boost: This acquisition will provide a significant boost to Mankind Pharma's biologics plans, enhancing their capabilities in this advanced field. 🌎 Global Reach: BSV’s operations span over 70 countries, with subsidiaries in Germany, the Philippines, and the US, further strengthening Mankind Pharma's international footprint. MANKIND PHARMA LTD - Sheetal Arora

Mankind Pharma Completes Rs 13,768 Crore Acquisition of Bharat Serums MANKIND PHARMA LTD on Wednesday said it has completed the transaction to acquire Bharat Serums and Vaccines Limited (BSV), for a consideration of Rs 13,768 crore. This strategic move marks a significant leap for the company, positioning it as a market leader in the Indian women's health and fertility drug market alongside access to other high entry barrier products in critical care segment with established complex R&D tech platforms, the drug maker said in a statement. BSV, has developed recombinant and niche biologic products in-house, demonstrating its strong R&D capabilities and boasts of a robust branded product portfolio across women's health, fertility, critical care and immunoglobulins. Sanjiv Navangul, MD & CEO, BSV, said that being a part of the Mankind Pharma family makes BSV bigger, stronger and better. #MankindPharma #BSV #BharatSerumsandVaccines #R&D #RajeevJuneja #SanjivNavangul #acquistion

In the video, at the studio of ET Now Swadesh, Mumbai on 1 February, 2024, I was bullish on Nifty Pharma, but we have now turned neutral on the sector. During the bullish period from February 1, 2024 to October 10, 2024, Nifty Pharma saw significant growth, climbing from 17,839 to 23,305. Here’s how some key players performed: •Abbott India Ltd. rose from 25,887 to 28,346 •Ajanta Pharmaceuticals Ltd. jumped from 2,168 to 3,335 •Alkem Laboratories Ltd. increased from 4,854 to 6,121 •Aurobindo Pharma Ltd.  climbed from 1,070 to 1,469.75 •Biocon Ltd. went up from 269 to 345.7 •Cipla Ltd. grew from 1,387 to 1,623 •Divi's Laboratories Ltd. surged from 3,655 to 5,950 •Dr. Reddy's Laboratories Ltd. saw an increase from 5,993 to 6,581 •Gland Pharma Ltd. dropped from 1,983 to 1,706 •Glenmark Pharmaceuticals Ltd. rose from 890 to 1,758.50 •Granules India Ltd. moved from 412 to 579 •Ipca Laboratories Ltd. increased from 1,114 to 1,595 •Laurus Labs Ltd. grew from 389 to 466 •Lupin Ltd. jumped from 1,513 to 2,158 •Mankind Pharma Ltd. rose from 2,046 to 2,681 •NATCO Pharma Ltd. increased from 869.3 to 1,445 •Sun Pharmaceutical Industries Ltd. climbed from 1,407 to 1,894 •Torrent Pharmaceuticals Ltd. surged from 2,512 to 3,448 •Zydus Lifesciences Ltd. rose from 729.55 to 1,057.90 While the overall trend has been positive, our current stance reflects a more neutral outlook on the sector. Stay tuned for more insights!

Thoughts on this? >> #EHA24: Roche details overall survival data on bispecific antibody Columvi >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #healthcare #biotech

Thoughts on this? >> #EHA24: Roche details overall survival data on bispecific antibody Columvi >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #pharmaceutical #productmarketing #healthcare

CIN & HR-HPV treatment Market Research Report: #CIN & HR-HPV treatment Market Size, Share & Trends Analysis Report (By End User, By Product Type), Global Economy Insights, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023 - 2031. Global CIN & HR-HPV #treatment #Market size was valued at USD 12.65 Billion in 2022 and is projected to reach USD 22.68 Billion by 2031, growing at a CAGR of 6.7% from 2022 to 2031 according to a new report by IMIR Market Research. The CIN & HR-HPV treatment market #research report comprises a thorough #examination of the current and future scenario of this industry vertical. The research highlights major trends and opportunities, as well as challenges, for various segments and sub-segments, while broadening the company horizon. The study report also includes extensive #information based on past and present #patterns across several industry verticals to help find various expansion prospects. Throughout the forecast period, several #estimations regarding market share, market size, and industry growth rate are presented. The research includes information on competitive analysis as well as consumption habits and pricing #strategies depending on the CIN & HR-HPV treatment market. 📚𝗚𝗲𝘁 𝗧𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁𝗮𝘁 𝗗𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝗲𝗱 𝗣𝗿𝗶𝗰𝗲::👇 https://lnkd.in/dPtiRfp4 Antiva Biosciences, Inc.  Bioneer INOVIO Pharmaceuticals, Inc. QIAGEN  Thermo Fisher Scientific  Zilico Limited Abbott AbbVie  Antiva Biosciences, Inc.  Bavarian Nordic  Biocon Biological E. Limited Bioneer Bristol Myers Squibb  Cepheid Dynavax Technologies Fujirebio Europe  GSK  Immunomedics.  INOVIO Pharmaceuticals, Inc. Johnson & Johnson MedImmune  Merck Group. Moderna,  NantKwest,  Novartis Oncovir, Inc. ONO PHARMACEUTICAL CO., LTD. Pfizer  Serum Institute of India Pvt. Ltd. Shanghai Fosun Pharmaceutical Company Limited  Sinopharm Group Company Limited  Thermo Fisher Scientific Valneva  VBI Vaccines Inc. Zilico Limited 

𝐒𝐜𝐫𝐨𝐥𝐥 𝐫𝐢𝐠𝐡𝐭 𝐚𝐧𝐝 𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝 CATUG’𝐬 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐚𝐝𝐯𝐚𝐧𝐭𝐚𝐠𝐞 𝐢𝐧 𝐑𝐍𝐀 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 ➡️ During the COVID-19 pandemic, RNA vaccine technology expanded rapidly, but the fast development exposed significant challenges. The industry was not prepared or equipped for large-scale production, leading to a scattered and inefficient manufacturing process for RNA-based products/vaccines including: -A first site (A) to produce high-quality, high-purity pDNA -A second site (B) for IVT RNA starting from the pDNA template -A third site (C) for LNP Formulation/RNA Encapsulation, Fill & Finish These distributed processes (page1) often led to bottlenecks in logistics and supply chain, adding costs and time for both clients and patients. This problem still persists today, as only a few manufacturers are equipped to handle the whole manufacturing process. From inception, CATUG was conceived as a fully integrated CRDMO equipped for all parts of the process (see page 2). This gives us a competitive edge as we provide: •Streamlined, optimized logistics from pDNA → RNA → LNP → Fill & Finish •Reduced costs and time in transportation and distribution •A single point of contact for our clients •Fast delivery times from project start to full release Follow CATUG to stay updated and let’s get in touch to boost your products now! 🚀💉🔬 🇨🇭Switzerland BD team: Congyu (Chloe) Wu - Cesare Di Nitto www.catug.bio/contact #RNA #manufacturing #biotech #LNP #vaccines #COVID19 #CRDMO #pDNA #logistics #supplychain #innovation #biotechnology #healthcare #pharmaceuticals #biotechindustry #CATUG #RNAtherapeutics